BHVN icon

Biohaven

21.74 USD
+1.90
9.58%
At close Apr 28, 4:00 PM EDT
Pre-market
21.75
+0.01
0.05%
1 day
9.58%
5 days
3.72%
1 month
-21.37%
3 months
-43.34%
6 months
-57.99%
Year to date
-41.68%
1 year
-45.42%
5 years
-85.67%
10 years
-85.67%
 

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

98% more call options, than puts

Call options by funds: $34.9M | Put options by funds: $17.6M

61% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 64

15% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 40

0.91% more ownership

Funds ownership: 91.1% [Q3] → 92.01% (+0.91%) [Q4]

0% more funds holding

Funds holding: 253 [Q3] → 254 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 10 (+0) [Q4]

18% less capital invested

Capital invested by funds: $4.3B [Q3] → $3.51B (-$792M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$54
148%
upside
Avg. target
$61
182%
upside
High target
$68
213%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Baird
Brian Skorney
35% 1-year accuracy
8 / 23 met price target
162%upside
$57
Outperform
Maintained
28 Apr 2025
Morgan Stanley
Terence Flynn
36% 1-year accuracy
8 / 22 met price target
190%upside
$63
Overweight
Maintained
7 Mar 2025
JP Morgan
Tessa Romero
23% 1-year accuracy
3 / 13 met price target
213%upside
$68
Overweight
Maintained
5 Mar 2025
HC Wainwright & Co.
Douglas Tsao
25% 1-year accuracy
42 / 170 met price target
148%upside
$54
Buy
Reiterated
4 Mar 2025
RBC Capital
Leonid Timashev
24% 1-year accuracy
10 / 41 met price target
181%upside
$61
Outperform
Reiterated
4 Mar 2025

Financial journalist opinion

Based on 28 articles about BHVN published over the past 30 days

Positive
The Motley Fool
17 hours ago
Why BioHaven Stock Is Soaring Today
Shares of Biohaven (BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day.
Why BioHaven Stock Is Soaring Today
Neutral
PRNewsWire
23 hours ago
Biohaven Announces Investment up to $600 Million by Oberland Capital
Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales $250 million to be funded at closing $150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses NEW HAVEN, Conn. , April 28, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Investment up to $600 Million by Oberland Capital
Negative
The Motley Fool
3 days ago
Why Biohaven Stock Plummeted by More Than 15% Today
On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%.
Why Biohaven Stock Plummeted by More Than 15% Today
Neutral
Accesswire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
Accesswire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
PRNewsWire
6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
GlobeNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Neutral
GlobeNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Charts implemented using Lightweight Charts™